Plaque Psoriasis

New data indicates that increased risk for offspring in developing different disorders is associated with maternal alopecia areata exposure, expanding the available information on alopecia and maternal autoimmunity.

This study examined survival of brodalumab after switching from ixekizumab, providing more information on real-world, non-medical switching for patients with psoriasis.

New data indicates the usefulness of spironolactone as an alternative to oral antibiotics for women in the UK with acne vulgaris, given increasing resistance to antibiotics due to widespread use.

New data from a systematic review of randomized control trials indicated that moderate-to-severe psoriasis patients benefited from deucravacitinib as a first line treatment.

In this interview, Marinkovich discussed the implications of the FDA’s landmark approval of B-VEC topical gene therapy for patients with the “butterfly disease.”

During this interview segment, Stucky continued on his team's findings on a newspaper article’s association with increased prescribing rates of oral minoxidil, explaining the study’s limitations and implications.

The long-awaited FDA approval follows data that demonstrated about 70% wound closure by 6 months in dystrophic epidermolysis bullosa patients treated with B-VEC.

A new research letter highlighted findings that show a lack of viral reactivation in hepatitis patients with psoriasis, as well as other strong results, opening the door for new studies to confirm these findings.

A review of randomized clinical trials using the World Health Organization’s framework for clinical adherence to point to key knowledge gaps in self-exam knowledge among those at high risk for skin cancer.

New phase 3 data on patients with eczema in China and Japan showed that crisaborole, 2%, was efficacious and safe in patients aged 2 and older, lining up with data from studies done in Western countries.

New data indicates that biologic treatments for psoriasis patients were found not to be significantly affected by comorbidities in older patients, widening the understanding of biologic use in different subgroups.

New research shows that mental health, life quality, and symptoms of eczema may all be improved through self-compassion and online mindfulness training that is both scalable and accessible to many.

New data indicates an association between cardiovascular risk factors and psoriasis disease activity, shedding light on potential ways to identify and help those at risk for future heart issues.

New data suggests that anti-IL-17A biologics including ixekizumab showed strong self-reported results in signs and symptoms for psoriasis patients.

New data on using narrowband-UVB therapy for chronic plaque psoriasis found that the body’s lower limbs were the most difficult to treat, though excellent responses were still reported.

After spesolimab was found to be useful against generalized pustular psoriasis, this new analysis showed promising results for the treatment despite differences in demographics and other characteristics.

The research method, which provides better context into patient and caregiver perspective on the field, has increased nearly two-fold in prevalence since 2020.

New research found that certain systemic markers in psoriatic arthritis and psoriasis patients correlated with PASI scores, indicating the clinical relevance of platelets and neutrophils in inflammation.

A retrospective analysis shows patients unresponsive to either secukinumab, ixekizumab or brodalumab may benefit from another of them.

This interview featured Mehmi discussing a less well-known form of melanoma known as mucosal melanoma, a condition which he believes needs to be researched in greater depth.

Findings from a Canadian routine care study showed that brodalumab was found to be effective for those with plaque psoriasis, with future real-world setting studies needed to learn more.

This study evaluated tranexamic acid injection for post-acne vulgaris erythema, though its smaller sample size may require the findings to be reproduced in large-scale studies.

Linda Stein Gold, MD, and Bruce Strober, MD, PhD, place the safety data for deucravacitinib in clinical context.

Linda Stein Gold, MD, and Bruce Strober, MD, PhD, explore the phase 3 data for deucravacitinib, as well as the dosage, and lack of drug-drug interactions associated with it.

Research indicates that despite reports of high psychological stress among women in their 20s and 30s in China and Japan, awareness of stress’s effects on aging remain higher among health professionals.